Clinical trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of LW402 Tablets in Patients With Moderate to Severe Active Rheumatoid Arthritis
NCT06800157 is registered in ClinicalTrials.gov with Shanghai Longwood Biopharmaceuticals Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIa Study to Evaluate the Efficacy, Safety, and Tolerability of LW402 Tablets in Patients With Moderate to Severe Active Rheumatoid Arthritis
- Lead sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 27, 2023
- Completion date
- August 30, 2024
- Enrollment
- 72 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.